EGFR and non-small cell lung carcinoma: Numerous clinical studies have confirmed that compared with traditional platinum-based chemotherapy, EGFR tyrosine kinase inhibitors (EGFR-TKIs) exhibit significant advantages on objective response rate (ORR) and progression free survival (PFS) in the treatment of advanced NSCLC patients with EGFR mutations (2–5).